NCT00427440View on ClinicalTrials.gov

A Phase II Study to Treat Advanced Malignant Glioma

PHASE2CompletedINTERVENTIONAL

Enrollment

61

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

April 30, 2013

Conditions

Advanced Malignant Glioma

Interventions

DRUG

AMG 102 at 20 mg/kg

AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks

DRUG

AMG 102 at 10 mg/kg

AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY

NCT00427440 - A Phase II Study to Treat Advanced Malignant Glioma | Biotech Hunter | Biotech Hunter